Last hope? new combo targets liver cancer that beat previous treatments
Disease control
Recruiting now
This study tests whether adding the drug lenalidomide to ongoing targeted therapy and immunotherapy can help people with advanced liver cancer whose disease has worsened after multiple prior treatments. About 32 participants will receive the combination and be monitored for tumor…
Phase: PHASE2 • Sponsor: Shunda Du • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC